Short answer
A positive RET result can change medullary thyroid cancer risk and MEN2 surveillance. Calcitonin is one marker clinicians may use when evaluating C-cell activity or medullary thyroid cancer context, but it should not be treated like a do-it-yourself screening number after a genetic result. The exact RET variant, age, personal history, thyroid findings, and family history all matter.
How calcitonin fits
| Situation | Common next question | Why it matters |
|---|---|---|
| Positive germline RET result | What exact variant and risk category were reported? | Follow-up is variant-specific. |
| Calcitonin is elevated | Was endocrinology involved with thyroid imaging and history? | Single-marker interpretation can mislead. |
| Child or young relative is positive | Is pediatric endocrine genetics involved? | Some RET variants change childhood timing. |
What the result can and cannot show
Calcitonin can support a specialist's assessment, but it cannot by itself prove whether a RET result is clinically urgent, whether a thyroid problem is already present, or whether relatives need testing immediately. The safest interpretation is through a MEN2-aware endocrine genetics plan tied to the exact variant.
How follow-up is usually framed
Follow-up usually starts with the report wording, then moves to endocrinology or endocrine genetics, and then to age-appropriate thyroid and family planning questions. That sequence helps avoid overreacting to a single number while still taking RET seriously.
Questions to ask
- Is the RET result germline, tumor-only, or direct-to-consumer and needing clinical confirmation?
- Which clinician is coordinating calcitonin, thyroid ultrasound, adrenal screening, and family testing?
- Does the plan mention the exact RET variant rather than only saying positive?
- Should relatives receive targeted family-variant testing, and who will write the family letter?
When follow-up matters more
Follow-up matters more when a hereditary tumor result could change who in the family should be tested, when tumor-only and germline questions are still mixed together, or when a specialist plan should decide surveillance timing rather than a single lab result. Genetics counseling helps keep the finding tied to the actual family question.
FAQ
Why is calcitonin discussed after a positive RET result?
Because calcitonin can help clinicians think about C-cell activity and medullary thyroid cancer context, but it is only one part of follow-up.
Does a calcitonin result replace the RET result?
No. The RET variant and the clinical context still drive the long-term plan.
Who should order calcitonin follow-up?
Usually a clinician familiar with MEN2, such as endocrinology or endocrine genetics, not a do-it-yourself test interpretation.
Can a normal calcitonin rule everything out?
No. Normal calcitonin does not erase the need to interpret the exact RET variant, family history, and age-specific planning.
Should relatives also get calcitonin testing?
Not automatically. Relatives usually need targeted genetic counseling first, because the family-variant question comes before marker testing.
What should I ask at follow-up?
Ask who is coordinating MEN2 surveillance, whether calcitonin is being used as a marker or a screening test, and whether family letters are needed.